112 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2006 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 8 INTANGIBLE ASSETS CONTINUED Amortisation and impairment charges Amortisation charges are recorded in selling, general and administrative costs in the income statement.
The impairment in 2006 was in relation to the termination of NXY-059 and a collaboration agreement.
These costs were included in research and development in the income statement.
The impairment in 2004 was in relation to the write-off of goodwill associated with Exanta.
This cost was included in selling, general and administrative costs in the income statement.
For the purposes of impairment testing of goodwill, the Group is regarded as a single, cash-generating unit.
The cash-generating units recoverable amount is based on value in use using projections of the Groups performance over ten years, a period reflecting the patent-protected lives of our current products.
The projections include assumptions about product launches, competition from rival products, pricing policy as well as the possibility of generics entering the market.
The ten year period is covered by internal budgets and forecasts.
A risk-adjusted discount rate of 12% has been applied to the projections.
Tests on a similar basis are also conducted at geographic specific levels using proportionate allocations of cross-functional assets.
Significant assets Carrying Remaining value amortisation Description $m period Goodwill in the US Goodwill 707 Not amortised Intangible assets arising from joint venture with Merck Product, marketing and distribution rights 330 7 and 11 years Advance payment Product, marketing and distribution rights 715 12 years Intangible assets arising from the acquisition of CAT Product, marketing and distribution rights 603 9 and 14 years Intangible assets arising from the acquisition of KuDOS Product, marketing and distribution rights 285 Not amortised These assets are associated with the restructuring of the joint venture with Merck & Co. Inc.
Assets in development are not amortised.
9 OTHER INVESTMENTS 2006 2005 2004 $m $m $m Non-current investments Loans and receivables at fair value through profit or loss 37 100 76 Equity securities available-for-sale 82 156 186 119 256 262 Current investments Assets held for trading: Equity securities 22 12 14 Fixed deposits 559 1,549 1,065 Derivative financial instruments 76 63 119 657 1,624 1,198 An impairment of $nil in respect of an available-for-sale security 2005 $16m, 2004 $nil is included in research and development in the income statement.
In 2006, the Company completed the acquisition of Cambridge Antibody Technology Group plc, which was previously held as an available-for-sale investment.
